ARS Pharmaceuticals Posts $22.7M Revenue on Neffy Growth, Eyes CVS Caremark Approval
Event summary
- Q1 2026 revenue of $22.7M, with $17.5M from neffy U.S. sales
- CVS Caremark formulary approval pending, expected in early June
- Sales force expanded to 148 representatives
- Phase 2b CSU study interim population fully enrolled, Q4 2026 readout expected
- Net loss of $60.6M, cash runway sufficient through cash-flow break-even
The big picture
ARS Pharmaceuticals is positioning neffy as the first needle-free epinephrine treatment, addressing key limitations of traditional auto-injectors. The pending CVS Caremark approval and ongoing Medicaid expansions highlight the strategic importance of payor access in driving adoption. With a strong cash position, the company is balancing aggressive commercialization with clinical pipeline advancement, particularly in chronic spontaneous urticaria.
What we're watching
- Market Access Dynamics
- Whether CVS Caremark approval will drive significant prescription volume growth and how quickly other major payors follow.
- Clinical Pipeline Progress
- The pace at which the Phase 2b CSU study delivers interim data and whether it supports a Phase 3 pivotal study initiation in mid-2027.
- Commercial Execution
- How effectively ARS Pharmaceuticals can convert its expanded sales force and retail pharmacy program into sustained market share gains.
Related topics